Novel therapies in the treatment of ulcerative colitis

Bibliography

• LOFTUS EV, JR., SILVERSTEIN MD, SANDBORN WJ etal.: Ulcerative colitis in Olmsted County, Minnesota 1940–1993. Cut (2000) 46:336–343.
   Google Scholar
• •A good overview of the epidemiology of ulcerative colitis.
   Google Scholar
• SHIVANANDA S, LENNARD-JONES J, LOGAN R et al: Incidence of inflammatory bowel disease across Europe: is there any difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Cut (1996) 39:690–697.
   Google Scholar
• TRALLORI G, PALLID, SAIEVA C et al: A population-based study of inflammatory bowel disease in Florence over 15 years (1978-92). Scary/. J. Castroeriterol (1996) 31:892–899.
   PubMed Web of Science ®Google Scholar
• SATSANGI J, GROOTSCHOLTEN C, HOLT H, JEWELL DP: Clinical patterns of familial patterns of familial inflammatory bowel disease. Cut (1996) 38:738–741.
   Google Scholar
• •A nice epidemiological study of IBD.
   Google Scholar
• PARKES M, BARMADA MM, SATSANGI J, WEEKS DE, JEWELL DP, DUERR RH: The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn's disease. Am. j Hum. Cerra. (2000) 67:1605–1610.
   PubMed Web of Science ®Google Scholar
• DUERR RH, BARMADA MM, ZHANG L etal.: Linkage and association between inflammatory bowel diseases. Dig. Dis. (1998) 63:95–100.
   Google Scholar
• HUGOT JP, THOMAS G: Genome-wide scanning in inflammatory bowel diseases. Dig. Dis. (1998) 16:364–369.
   PubMed Web of Science ®Google Scholar
• SANDLER RS, WURZELMANN JI, LYLES CM: Oral contraceptive use and the risk of inflammatory bowel disease. Epidemiology (1992) 3:374–378.
   PubMed Web of Science ®Google Scholar
• HANAUER SB: Review articles: drug therapy: inflammatory bowel disease. N Engl. J. Med. (1996) 334:841–848.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of therapies for IBD.
   Google Scholar
• KORNBLUTH A, SACHAR DB: Ulcerative colitis practice guidelines in adults. Am. J. Castroeriterol (1997) 92:1867–1871.
   PubMedGoogle Scholar
• •A useful guide for clinicians.
   Google Scholar
• GIONCHETTI P, RIZZELLO VENTURI A et al: Comparison of oral with rectal meslzine in the treatment of ulcerative proectitis. Dis. Colon Rectum (1998): 41:93–97.
   PubMed Web of Science ®Google Scholar
• SAFDI M, DEMICCO M, SNINSKY C et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Castroeriterol (1997) 92:1867–1871.
   PubMed Web of Science ®Google Scholar
• KIRK AP, LENNARD-JONES JE: Controlled trial of azathioprine in chronic ulcerative colitis. Br. Med. j (1982) 284:1291–1292.
   PubMed Web of Science ®Google Scholar
• PRESENT DH, MELTZER SJ, KRUMHOLZ MP, WOLKE A, KORELITZ BI: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. (1989) 111:641–649.
   PubMed Web of Science ®Google Scholar
• LICHTIGER S, PRESENT DH, KORNBLUTH A et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy [see comments[. N Engl. I Med. (1994) 330:1841–1845.
   PubMed Web of Science ®Google Scholar
• MANTAZARIS GJ, HATZIS A, KONTOGIANNIS P, TRIADAPHYLLOU G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. (1994) 89:43–46.
   Google Scholar
• MANTAZARIS GJ, ARCHAVLIS E, CHRISTOFORIDIS P etal.: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. (1997) 92:454–456.
   Google Scholar
• TURUNEN UM, FARKKILA MA, HAKALA K et al.: Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective double-blind, placebo controlled study. Gastroenterology (1998) 115:1072–1078.
   PubMed Web of Science ®Google Scholar
• REMBACKEN BJ, SNELLING AM, HAWKEY PM, CHALMERS DM: Axon AT: Non-pathogenic Echerichia coil versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 354:635–639.
   PubMed Web of Science ®Google Scholar
• KRUIS W, SCHUTZ E, ERIC E FIXA B, JUDMAIER G, STOLTE M: Double-blind comparison of an oral Echerichia coil preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol. Ther. (1997) 11:853–858.
   PubMed Web of Science ®Google Scholar
• SHANAHAN F: Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inllamm. Bowel Dis. (2000) 6:107–115.
   PubMed Web of Science ®Google Scholar
• MCKRAIG BC, STACK WA: Novel approaches to inflammatory bowel disease. Expert Opiri. Investig. Drugs (1998) 7:1099–1113.
   PubMedGoogle Scholar
• PRESENT DH, RUTGEERTS E TARGAN S etal.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N ErigL j Med. (1999) 340:1398–1405.
   Google Scholar
• TARGAN SR, HANAUER SB, VAN DEVENTER SJ et aL: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. ErigL J. Med. (1997) 337:1029–1035.
   PubMed Web of Science ®Google Scholar
• •The landmark paper discussing chimeric antibodies to treat Crohn's disease.
   Google Scholar
• VASILIAUSKAS E, KAM LY, ABREU-MARTIN MT et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 117:1278–1287
   PubMed Web of Science ®Google Scholar
• EHRENPREIS E, KANE SV, COHEN LB; COHEN RC; HANAUER SB: Thalidomide therapy for patients with refractory Crohn's: An open-label trial. Gastroenterology (1999) 117:1271–1277.
   PubMed Web of Science ®Google Scholar
• COLE M, ANISETTI C, TSO J: Human IgG2 variants of chimeric Anti-CD3 are non-mitogenic to T cells. j IinmurioL (1997) 159:3613.
   PubMed Web of Science ®Google Scholar
• COLE M, STELLRECHT KE, SHI JD et aL: HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity In vitro. Transplantation (1999) 68:563.
   PubMed Web of Science ®Google Scholar
• CARPENTER P, COREY L, TSO JY et aL: Humanized non-FCR-binding anti-CD3 antibody as therapy for glucocorticoid refractory acute GVHD. Am. Soc. Hematol (2000) (Abstract).
   Google Scholar
• HAMANN A, ANDREW DP, JABLONSHI-WESTRICH D, HOLZMAN D, BUTCHER EC: Role of alpha-4 integrins in lymphocyte homing to mucosal tissues in vivo. fhnmuriol (1994) 152:3282–3293.
   Google Scholar
• BARGATZE R, JUTILA A, BUTCHER EC: Distinct roles of L-selectin and integrins a4137 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multi-step model confirmed and refined. Immunity(1995) 3:99–108.
   PubMed Web of Science ®Google Scholar
• SCHWEIGHOFFER T, TANAKA Y, TIDSWELL M etal.: Selective expression of integrin a4l37 on a subset of human CD4+ memory T cells with hallmarks of gut-tropism. J. Immuna (1991) 151:717–729.
   Google Scholar
• BRISKIN M, WINSOR-HINES D, SHYJAN A et aL: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. PathoL (1997) 151:97–110.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK, LOBB R, KING N et aL: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. I Clin. Invest. (1993) 92:372–380.
   PubMed Web of Science ®Google Scholar
• HESTERBERG PE, WINSOR-HINES D, BRISKIN MJ et aL: Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. I Clin. Invest. (1993) 92:372–380.
   PubMed Web of Science ®Google Scholar
• FEAGAN B, MCDONALD JW, GREENBERG G et aL: An ascending dose trial of a humanized a4137 antibody in ulcerative colitis. Am. GastroenteroL Soc. (Abstract).
   Google Scholar
• REIMUND J, DUMONT S, MULLER CD et aL: In vitro effects of oxypentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut (1997) 40:475–480.
   PubMed Web of Science ®Google Scholar
• HAAPAMAKI M, GRONROOS JM, NURM H, ALANEN K, KALLAJOKI M, NEVALAINEN TJ: Gene expression of group II phospholipase A2 in intestine in ulcerative colitis. Gut (1997) 40:95–101.
   PubMed Web of Science ®Google Scholar
• MINAMIT T, SHINOMURA Y, KOMATSUBURA T, MATSUSAWA Y, OKAMOTO M: Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis. Am. J. GastroenteroL (1993) 88:1076–1080.
   PubMed Web of Science ®Google Scholar
• MARTIN G: The role of FGFs in the early development of vertebrate limbs. Genes Dev. (1998) 12:1571–1586.
   PubMed Web of Science ®Google Scholar
• SEKINE K, OHUCHI H, FUJIWARA M et aL: FGF-10 is essential for limb and lung formation. Nat. Genet. (1999) 21:138–141.
   PubMed Web of Science ®Google Scholar
• MASHIMO H: Impaired defense of intestinal trefoil factor. Science (1996) 274:262–265.
   PubMed Web of Science ®Google Scholar
• PILLAI RB, TOLIA B, RABAH R, SIMPSON PM, BIJESURIER R, LIN CH: Increased colonic ornithine decarboxylase activity in inflammatory bowel disease in children. Dig. Dis. Sci. (1999) 44:1565–1570.
   PubMed Web of Science ®Google Scholar
• RICCI G, STABELLINI G, BERSANI G et al.: Ornithine decarboxylase in colonic mucosa from patients with moderate or severe Crohn's disease and ulcerative colitis. Eur. j GastroenteroL HepatoL (1999) 11:903–904.
   PubMed Web of Science ®Google Scholar
• RICE KD, WANG VR, GANGLOFF AR et aL: Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity. Bioorg. Med. Chem. Lett. (2000) 10:2361–2366.
   Google Scholar
• WARE JH, WAN XS, NEWBERNE P, KENNEDY AR: Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig. Dis. Sci. (1999) 44:986–990.
   PubMed Web of Science ®Google Scholar
• TIZARD I, BUSBEE D, MAXWELL B, KEMP MC: Effects of acemannan, a complex carbohydrate, on wound healing in young and aged rats. Wounds: Compendium of Clinical Research and Practice (1994) 6:201–209.
   Web of Science ®Google Scholar
• ROBINSON M, REICH C, LASHNER B et aL: Evaluation of oral acemannan in active ulcerative colitis. Proc. Meet. Am. Coll. GastroenteroL San Francisco, USA (1994).
   Google Scholar
• •A detailed abstract on the evaluation of oral acemannan in active ulcerative colitis.
   Google Scholar
• RAMDIN L, PERKS B, SHERON N, SHUTE JK: Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin. Clin. Exp. Allergy (1998) 28:616–624.
   PubMed Web of Science ®Google Scholar
• EGGESBO JB, HJERMANN I, HOSTMARK AT, KIERULF P: LPS induced release of IL-13, IL-6, IL-8 and TNF-a2-macroglobulin. Chia. Exp. Allergy (1998) 28:616–24.
   PubMedGoogle Scholar
• EVANS R, SHIM WONG V, MORRIS AJ, RHODES JM: Treatment of corticosteroid-resistant ulcerative colitis with heparin- a report of 16 cases. Ailment Pharmacol. Ther (1997) 11:1037–1040.
   PubMed Web of Science ®Google Scholar
• FOLWACZNY C, WIEBECKE B, LOESCHKE K: Unfractionated heparin in the therapy of patient with highly active inflammatory bowel disease. Am. Castroenterol (1999) 94:1551–1555.
   PubMed Web of Science ®Google Scholar
• GAFFNEY PR, OL JJ, DOYLE CT et al:Response to heparin in patients with ulcerative colitis [letter]. Lancet (1991) 337:238–239.
   PubMed Web of Science ®Google Scholar
• GAFFNEY PR, DOYLE CT, GAFFNEY A, HOGAN J, HAYES DP, ANNIS P: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am. Castroenterol (1995) 90:220–223.
   PubMed Web of Science ®Google Scholar
• KORZENIK J, ROBERT ME, BITTON A et al.: A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis. Proc. Am. Coll. Castroenterol Meeting. Chicago, USA (1998).
   Google Scholar
• •A detailed abstract on the treatment of ulcerative colitis with heparin.
   Google Scholar
• TAUSSIG SJ, YOKOYAMA MM, CHINEN A, ONARI K, YAMAKIDO M: Bromelain: a proteolytic enzyme and its clinical application. (Review). Hiroshima Med. Sci. (1975) 24:185–193.
   PubMed Web of Science ®Google Scholar
• MORI S, OJIMAY, HIROSE T, SASAKI T,HASHIMOTO Y: The clinical effect of proteolytic enzyme containing bromelain and trypsin on urinary tract infection evaluated by double blind method. Acta Obstet. Cyriaecol. hirr. (1972) 19:147–153.
   Google Scholar
• KUMAKURA S, YAMASHITA M, TSURFUJI S: Effect of bromelain on kaolin-induced inflammation in rats. Eur. Pharmacol (1988) 150:295–301.
   PubMed Web of Science ®Google Scholar
• KANE S, GOLDBERG MJ: Use of bromelain for mild ulcerative colitis. Ann. Intern. Med. (2000) 132:680.
   PubMed Web of Science ®Google Scholar
• MAEMOTO A, ASHIDA T, NOMURA M et al.: Remission-inducing potential of Centrifugal leukocyte apheresis in refractory patients with active ulcerative colits. Proc. Meeting Am. Castroenterol Ass San Diego, USA (2000).
   Google Scholar
• •An intriguing study using apheresis rather than medications to treat ulcerative colitis.
   Google Scholar